Regeneron Pharmaceuticals Inc (REGN)
513.69
-2.34 -0.45%
NASDAQ
Dec 1, 16:20
USD
Regeneron Pharmaceuticals PE Ratio:
18.78 for Dec. 1, 2020View 4,000+ financial data types
Browse...
View Full Chart
PE Ratio Chart
Export Data
Save Image
Print Image
For advanced charting, view our full-featured
Fundamental Chart
Historical PE Ratio Data
View and export this data going back to 2004.
Start your Free Trial
Export Data
Date Range:
| Data for this Date Range | |
|---|---|
| Dec. 1, 2020 | 18.78 |
| Nov. 30, 2020 | 18.86 |
| Nov. 27, 2020 | 18.79 |
| Nov. 25, 2020 | 18.58 |
| Nov. 24, 2020 | 18.50 |
| Nov. 23, 2020 | 19.14 |
| Nov. 20, 2020 | 18.96 |
| Nov. 19, 2020 | 18.81 |
| Nov. 18, 2020 | 18.97 |
| Nov. 17, 2020 | 19.67 |
| Nov. 16, 2020 | 20.44 |
| Nov. 13, 2020 | 20.70 |
| Nov. 12, 2020 | 20.35 |
| Nov. 11, 2020 | 20.75 |
| Nov. 10, 2020 | 20.44 |
| Nov. 9, 2020 | 20.74 |
| Nov. 6, 2020 | 21.13 |
| Nov. 5, 2020 | 21.52 |
| Nov. 4, 2020 | 21.46 |
| Nov. 3, 2020 | 20.37 |
| Nov. 2, 2020 | 20.05 |
| Oct. 30, 2020 | 19.87 |
| Oct. 29, 2020 | 20.31 |
| Oct. 28, 2020 | 20.73 |
| Oct. 27, 2020 | 21.29 |
| Oct. 26, 2020 | 21.41 |
| Oct. 23, 2020 | 21.19 |
| Oct. 22, 2020 | 21.04 |
| Oct. 21, 2020 | 20.92 |
| Oct. 20, 2020 | 21.08 |
| Oct. 19, 2020 | 21.31 |
| Oct. 16, 2020 | 21.92 |
| Oct. 15, 2020 | 21.39 |
| Oct. 14, 2020 | 21.96 |
| Oct. 13, 2020 | 22.22 |
| Oct. 12, 2020 | 21.99 |
| Oct. 9, 2020 | 22.01 |
| Oct. 8, 2020 | 21.93 |
| Oct. 7, 2020 | 21.63 |
| Oct. 6, 2020 | 21.26 |
| Oct. 5, 2020 | 22.12 |
| Oct. 2, 2020 | 20.64 |
| Oct. 1, 2020 | 20.77 |
| Sept. 30, 2020 | 20.46 |
| Sept. 29, 2020 | 22.21 |
| Sept. 28, 2020 | 22.14 |
| Sept. 25, 2020 | 22.22 |
| Sept. 24, 2020 | 21.58 |
| Sept. 23, 2020 | 21.88 |
| Sept. 22, 2020 | 22.13 |
| Sept. 21, 2020 | 21.51 |
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
Advertisement
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS (ttm). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Benchmarks
| Moderna Inc | -- |
| Amgen Inc | 18.15 |
| Gilead Sciences Inc | 63.02 |
PE Ratio Range, Past 5 Years
| Minimum | 14.18 | Jun 06 2019 |
| Maximum | 109.10 | Dec 16 2015 |
| Average | 36.93 |
News
New Advances in Treating Difficult Blood Cancers From Johnson & Johnson and Others
Yahoo 12/01 14:23 ET
Yahoo 12/01 14:23 ET
Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual Meeting
PR Newswire 11/30 07:00 ET
PR Newswire 11/30 07:00 ET
Sanofi, Regeneron Win Approval by European Commission for Dupixent to Treat Eczema in Children
MT Newswires 11/30 04:39 ET
MT Newswires 11/30 04:39 ET
EC OKs expanded use of Sanofi/Regeneron's Dupixent for children with atopic dermatitis
SA Breaking News 11/30 04:31 ET
SA Breaking News 11/30 04:31 ET
Advertisement
